Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Antimicrob Chemother ; 78(7): 1757-1768, 2023 07 05.
Artigo em Inglês | MEDLINE | ID: mdl-37264485

RESUMO

OBJECTIVES: To uncover clinical epidemiology, microbiological characteristics and outcome determinants of hospital-acquired bloodstream infections (HA-BSIs) in Turkish ICU patients. METHODS: The EUROBACT II was a prospective observational multicontinental cohort study. We performed a subanalysis of patients from 24 Turkish ICUs included in this study. Risk factors for mortality were identified using multivariable Cox frailty models. RESULTS: Of 547 patients, 58.7% were male with a median [IQR] age of 68 [55-78]. Most frequent sources of HA-BSIs were intravascular catheter [182, (33.3%)] and lower respiratory tract [175, (32.0%)]. Among isolated pathogens (n = 599), 67.1% were Gram-negative, 21.5% Gram-positive and 11.2% due to fungi. Carbapenem resistance was present in 90.4% of Acinetobacter spp., 53.1% of Klebsiella spp. and 48.8% of Pseudomonas spp. In monobacterial Gram-negative HA-BSIs (n = 329), SOFA score (aHR 1.20, 95% CI 1.14-1.27), carbapenem resistance (aHR 2.46, 95% CI 1.58-3.84), previous myocardial infarction (aHR 1.86, 95% CI 1.12-3.08), COVID-19 admission diagnosis (aHR 2.95, 95% CI 1.25-6.95) and not achieving source control (aHR 2.02, 95% CI 1.15-3.54) were associated with mortality. However, availability of clinical pharmacists (aHR 0.23, 95% CI 0.06-0.90) and source control (aHR 0.46, 95% CI 0.28-0.77) were associated with survival. In monobacterial Gram-positive HA-BSIs (n = 93), SOFA score (aHR 1.29, 95% CI 1.17-1.43) and age (aHR 1.05, 95% CI 1.03-1.08) were associated with mortality, whereas source control (aHR 0.41, 95% CI 0.20-0.87) was associated with survival. CONCLUSIONS: Considering high antimicrobial resistance rate, importance of source control and availability of clinical pharmacists, a multifaceted management programme should be adopted in Turkish ICUs.


Assuntos
Bacteriemia , COVID-19 , Infecção Hospitalar , Sepse , Humanos , Masculino , Feminino , Estudos Prospectivos , Estudos de Coortes , Infecção Hospitalar/microbiologia , Unidades de Terapia Intensiva , Fatores de Risco , Carbapenêmicos , Hospitais , Bacteriemia/tratamento farmacológico , Bacteriemia/epidemiologia , Bacteriemia/microbiologia
2.
Saudi Med J ; 27(5): 637-41, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16680252

RESUMO

OBJECTIVE: To compare the effects of crystalloid and colloid solutions, tranexamic acid and epsilon-aminocaproic acid on the need for allogenic blood transfusion and on coagulation and fibrinolysis parameters. METHODS: We conducted the study in the Anesthesiology and Reanimation Department of Hacettepe University Medical Faculty, Ankara, Turkey between March 2004 and April 2005. The study included 105 patients, classified by the American Society of Anesthesiology as physical status groups I-II, undergoing gynecologic cancer treatment. We divided them into 5 groups: group I (crystalloid) received crystalloid solutions, group II (colloid) received colloid solutions, group III (tranexamic acid) received 10 mg x kg(-1) tranexamic acid, and group 5 (epsilon-aminocaproic acid) received 100 mg x kg(-1) epsilon-aminocaproic acid. All patients bleeding amount was measured and recorded perioperatively, and at the 12th and 24th hours postoperatively. We then evaluated the patients' hemoglobin, hematocrit, activated thromboplastin time, international normalized ration, fibrinogen, and thrombocyte count and symptoms of pulmonary embolism. RESULTS: In comparing the amount of bleeding, the bleeding in the tranexamic acid group was 30.8% less than the crystalloid group (p<0.05), 33.3% less than the colloid group (p<0.05), and 23.9% less than the epsilon-aminocaproic acid group (p<0.05). CONCLUSION: When the negative effects of blood transfusions were considered, tranexamic acid administration can be recommended for decreasing the need for blood transfusion in gynecologic cancer surgery.


Assuntos
Ácido Aminocaproico/administração & dosagem , Antifibrinolíticos/administração & dosagem , Coloides/administração & dosagem , Neoplasias dos Genitais Femininos/cirurgia , Soluções Isotônicas/administração & dosagem , Ácido Tranexâmico/administração & dosagem , Coagulação Sanguínea/fisiologia , Soluções Cristaloides , Feminino , Fibrinogênio/análise , Fibrinólise/fisiologia , Hematócrito , Hemoglobinas/análise , Humanos , Coeficiente Internacional Normatizado , Tempo de Tromboplastina Parcial , Contagem de Plaquetas , Embolia Pulmonar/diagnóstico , Turquia
3.
Middle East J Anaesthesiol ; 18(2): 407-19, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-16438016

RESUMO

The purpose of this study is to evaluate the usefulness of Cisatracurium Besilat (CB), and the method of its administration during laparotomies on adult patients, to determine whether CB caused cutaneous, systemic or chemical evidence of histamine release. This study was conducted as a randomized, double-blind clinical trial on 38 patients (ASA I-II). After a standard anesthetic induction with fentanyl and propofol, patients received an i.v. bolus CB (0.15 mg/kg in Group A (n=20) or Group B (n=18). In Group B, 0.18 mg/kg/h infusion was started. Following reaching stable muscle relaxations for intraabdominal operation and for recovery, Group A (Bolus group) and Group B (Infusion group) were compared. Train-of-four fade during recovery of block were recorded after administration of CB. The heart rate and arterial blood pressure were monitored noninvasively. There were no significant hemodynamic differences among the groups. 25%-75% spontaneous recoveries were (mean+/-s) 12.75+/-4.52, 16.11+/-9.20 minutes for Group A, Group B. 70% TOF Ratios were (mean+/-s) 1.07+/-0.13, 1.39+/-0.38 hours for the same groups. There was no consistent correlation between hemodynamic changes, cutaneous manifestations and histamine concentrations. We conclude that CB does not cause systemic or cutaneous histamine release. The infusion method of cisatracurium has a stable level of curarization without side effect and there were no significant recovery time differences between the groups.


Assuntos
Atracúrio/análogos & derivados , Bloqueadores Neuromusculares/administração & dosagem , Abdome/cirurgia , Adulto , Idoso , Análise de Variância , Período de Recuperação da Anestesia , Atracúrio/administração & dosagem , Atracúrio/efeitos adversos , Pressão Sanguínea/efeitos dos fármacos , Método Duplo-Cego , Eletrocardiografia/métodos , Frequência Cardíaca/efeitos dos fármacos , Histamina , Humanos , Infusões Intravenosas/métodos , Injeções Intravenosas/métodos , Pessoa de Meia-Idade , Monitorização Intraoperatória/métodos , Bloqueadores Neuromusculares/efeitos adversos , Pele/efeitos dos fármacos , Fatores de Tempo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA